HAON Life Sciences Secures €10.7M to Advance Allogeneic Cell Therapy for Infant Brain Injury

Published on Spencer Knight via LinkedIn

HAON Life Sciences, a Dublin-based biotech startup, has received €10.7 million from Ireland’s DTIF to develop CanVas-001. This allogeneic cell therapy targets Hypoxic Ischemic Encephalopathy (HIE), a severe brain injury caused by oxygen deprivation during birth, often resulting in lifelong disability or death.

CanVas-001 combines two regenerative cell types, Endothelial Colony Forming Cells and Mesenchymal Stromal Cells, to reduce inflammation and restore vascular function. Being allogeneic, it can be manufactured at scale and delivered rapidly in critical care settings. Spencer Knight calls it a major step for neonatal medicine and scalable regenerative care.

Read the full article via The Currency:

👉 Irish HAON Life Sciences receives €10.7M grant to heal infant brain injuries

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full details, please refer to the original article via the provided link.